Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge. 2021

Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
Department of Hematology, Ankara Dıskapı Research and Training Hospital, Ankara, Turkey.

BACKGROUND Synchronous detection of multiple myeloma and acute myeloid leukemia in a single patient is a rare coincidence. Treatment of these patients is still unclear, mostly based on acute myeloid leukemia strategies combined with bortezomib. METHODS A 72-year-old male with no medical history was investigated for pancytopenia. On medical examination, he was complicated with a wide and severe skin infection on arm. On examination of bone marrow aspirate, 25% myeloblasts infiltration and additional 10% plasma cells were seen. Acute myeloid leukemia was diagnosed and plasma cell proliferation was attributed to reactive plasmacytosis due to skin infection. However, flowcytometric studies and immunohistochemical examination revealed two different cell populations with 30-40% atypical plasma cells and >20% myeloblasts. Serum M-protein detected by serum electrophoresis test and immunofixation test revealed a monoclonal IgG lambda band. He was diagnosed with concurrent acute myeloid leukemia and multiple myeloma without history of chemotherapy.Management and outcome: The patient was initially treated with bortezomib and dexamethasone for the myeloma. Subsequently, azacitidine was administered subcutaneously for the acute myeloid leukemia treatment. The tru-cut biopsy of the lesion on his arm revealed suppurative inflammatory findings and no malign cells detected. Antibiotherapy was started according to susceptibility. He expired after three months of survival. CONCLUSIONS The synchronous occurrence of these two different clonal hematological malignancies is rare in hematology practice. Patient-based prospective studies and case series are needed to guide diagnosis and treatment strategies. Furthermore, this report highlights the importance of ruling out reactive plasmacytosis in patients with hematological malignancy who developed severe infections.

UI MeSH Term Description Entries
D008297 Male Males
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009194 Myeloma Proteins Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA. M Components,Proteins, Myeloma
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic

Related Publications

Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
September 2017, Blood research,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
October 2019, Blood,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
December 2006, Turkish journal of haematology : official journal of Turkish Society of Haematology,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
January 2020, Leukemia research reports,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
April 2022, Clinical case reports,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
May 1975, Human pathology,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
August 2017, BMJ case reports,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
October 2015, BMC cancer,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
January 2018, Current problems in cancer,
Senem Maral, and Murat Albayrak, and Osman Sahin, and Hacer Berna Afacan Ozturk, and Unsal Han, and Mesude Falay
September 2022, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!